Navigation Links
Jiangbo Pharmaceuticals Announces Fourth Quarter and Fiscal Year 2010 Results
Date:9/30/2010

he U.S. Securities and Exchange Commission and is available on the Company's website.

Fiscal Year 2010 Corporate Event Highlights -- On June 8, 2010, Jiangbo's common stock began trading on The NASDAQ Global Market -- On June 10, 2010, Jiangbo announced that it had obtained SFDA approval to produce Felodipine sustained release tablets, which is a well recognized generic drug to treat hypertension -- Effective July 1, 2010, Mr. Linxian Jin took over the role of CEO from the Company's Chairman, Mr. Wubo Cao, who will continue his role as the Chairman of the Company's Board Fourth Quarter FY 2010 Highlights: -- Revenues decreased 5.9% year-over-year to $29.3 million -- Gross profit was $21.1 million, a 8.2% decrease from the comparable period in 2009 -- Operating income decreased 17.1% year-over-year to $14.7 million -- Net income decreased 37.5% to $7.2 million, or $(0.39) per fully diluted share -- Non-GAAP adjusted net income was $9.8 million, or $0.65 per fully diluted share, for the three months ended June 30, 2010, down 19.1% from non-GAAP adjusted net income of $12.1 million, or $0.81 per fully diluted share, for the quarter ended June 30, 2009 Fiscal Year 2010 Highlights: -- Total revenue decreased 17.0% year-over-year to $97.4 million -- Gross profit decreased 20.3% to $71.3 million, as compared to the results in fiscal year 2009 -- Operating income decreased 3.1% year-over-year to $48.2 million -- Net income grew 3.4% to $29.9 million, as compared to the results in fiscal year 2009 -- Non-GAAP adjusted net income was $30.9 million, or $2.04 per fully diluted share in fiscal year of 2010, down 13.0% from non-GAAP adjusted net income of $35.6 million, or $2.46 per fully diluted share in fiscal year 2009

"Fiscal year 2010 was a transitional year for Jiangbo as we worked to upgrade our traditional Chinese medicine ("TCM") production facility and prepared for the introduction of new drugs. We are very pleased to have our shares begin trading on
'/>"/>

SOURCE Jiangbo Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18

Related medicine technology :

1. Jiangbo Pharmaceuticals Chairman to Ring NASDAQ Opening Bell on August 27, 2010
2. Jiangbo Pharmaceuticals Announces the Commercial Launch of Felodipine Sustained Release Tablets
3. Jiangbo Pharmaceuticals to Attend Global Hunter Securities China Conference
4. Jiangbo Pharmaceuticals Announces the Appointment of New Chief Executive Officer
5. Jiangbo Pharmaceuticals, Inc. Receives Approval to List on the NASDAQ Global Market
6. Jiangbo Pharmaceuticals Reports Results for Third Quarter of Fiscal Year 2010
7. Jiangbo Pharmaceuticals Reports Results for the Second Quarter of its Fiscal Year 2010
8. Jiangbo Pharmaceuticals Announces Conference Call to Discuss Results for Its Second Quarter of Fiscal Year 2010
9. Jiangbo Pharmaceuticals Osteomyelitis Treatment Tablets to be Included in Chinas National Insurance Directory
10. Jiangbo Pharmaceuticals Obtains Renewal of GMP Certificate
11. Jiangbo Pharmaceuticals Announces First Quarter Fiscal Year 2010 Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/27/2015)... , March 27, 2015 According ... Product (Diagnostic Catheter (Conventional, Advanced, Ultrasound), Ablation Catheter (Cryoablation, ... & Indication (AF, VT, WPW) - Global Forecasts to ... expected to reach around ~$4.73 Billion by 2019 with ... 2014 to 2019. Browse   90 ...
(Date:3/27/2015)... Mass. , March 27, 2015 /PRNewswire/ ... and privately-held MirImmune LLC, today announced that ... agreement to RXi,s novel and proprietary sd-rxRNA® ... cancer immunotherapies. The collaboration has the potential ... patient friendly cancer treatments that could be ...
(Date:3/27/2015)... 27, 2015 Concord Medical Services Holdings ... CCM ), a leading specialty hospital management solution ... radiotherapy and diagnostic imaging centers in ... a purchase agreement under which Concord Medical Services ... the Company, agreed to acquire the Fortis Surgical ...
Breaking Medicine Technology:Electrophysiology (EP) Market Worth $4.73 Billion by 2019 2Electrophysiology (EP) Market Worth $4.73 Billion by 2019 3Electrophysiology (EP) Market Worth $4.73 Billion by 2019 4RXi Pharmaceuticals and MirImmune LLC Enter into an Exclusive Licensing Agreement for RXi's Self-Delivering RNAi (sd-rxRNA) Technology to Develop Cell-based Immunotherapies to Treat Cancer 2RXi Pharmaceuticals and MirImmune LLC Enter into an Exclusive Licensing Agreement for RXi's Self-Delivering RNAi (sd-rxRNA) Technology to Develop Cell-based Immunotherapies to Treat Cancer 3RXi Pharmaceuticals and MirImmune LLC Enter into an Exclusive Licensing Agreement for RXi's Self-Delivering RNAi (sd-rxRNA) Technology to Develop Cell-based Immunotherapies to Treat Cancer 4RXi Pharmaceuticals and MirImmune LLC Enter into an Exclusive Licensing Agreement for RXi's Self-Delivering RNAi (sd-rxRNA) Technology to Develop Cell-based Immunotherapies to Treat Cancer 5Concord Medical Announces Acquisition of Fortis Surgical Hospital in Singapore 2Concord Medical Announces Acquisition of Fortis Surgical Hospital in Singapore 3
(Date:3/28/2015)... Rocket Pure , a manufacturer of natural body ... new natural sunscreen. They are offering the sunscreen in ... come with a bonus lip balm sunscreen. , The new ... Click to see the natural sunscreen on Amazon . ... made with non-nano zinc oxide and provides broad-based protection against ...
(Date:3/28/2015)... With more than 4,500 scientists, clinicians ... osteoarthritis and musculoskeletal diseases gathered here for the ... first time in the 17-year history of the ... topic is an emerging non-pharmaceutical protocol for enhancing ... of Wolff’s law, osteogenic loading at multiples of ...
(Date:3/28/2015)... An article in Fortune on Monday, March ... to organizations that deal with PCI (Payment Card Information); ... security, is worsening . Using numbers from Verizon’s ... category out of the twelve measured improved, barring one ... craziness that has gone on in the retail industry ...
(Date:3/28/2015)... 28, 2015 Delaying rotator cuff surgery ... according to research presented today at the American Orthopaedic ... , “Our study compared results for 170 patients who ... additional glenohumeral joint capsule release procedure to relieve stiffness ... PhD, lead author from St. George Hospital in Sydney, ...
(Date:3/28/2015)... Aureus Medical Group (web: aureusmedical.com), a ... jobs, has announced that it will participate as ... Annual Conference to be held April 10-11, 2015 ... OH. , The OPTA Annual Conference offers ... and services. , Representatives from Aureus Medical’s ...
Breaking Medicine News(10 mins):Health News:Rocket Pure Releases New Natural Sunscreens For Athletes 2Health News:Rocket Pure Releases New Natural Sunscreens For Athletes 3Health News:Non-Drug Protocol for Building Bone Density Expected to Steal Spotlight at World Congress on Osteoporosis 2Health News:Businesses Dealing With PCI Falling Short On Regular Vulnerability Scans and Pen Testing 2Health News:Businesses Dealing With PCI Falling Short On Regular Vulnerability Scans and Pen Testing 3Health News:Businesses Dealing With PCI Falling Short On Regular Vulnerability Scans and Pen Testing 4Health News:No Need to Delay Rotator Cuff Surgery, Study Shows 2Health News:Healthcare Staffing Leader, Aureus Medical Group, to Exhibit at the Ohio Physical Therapy Association Annual Conference 2
... WASHINGTON , April 18 The Federal Court ... unanimous 3-judge decision,today issued an opinion supporting the ... holding that it is entitled to renew its,constitutional ... Columbia,s AccessRx Act of 2004., Last year, ...
... April 18 Breckenridge Pharmaceutical,Inc. announced today that ... approval for the Company,s Abbreviated New Drug Application ... Activella Tablets,(Estradiol/Norethindrone Acetate 1.0mg / 0.5mg) Tablets., ... a,brand product marketed by Novo Nordisk(R), which is ...
... result of age, body composition , , FRIDAY, April 18 ... younger age or body composition may not explain why ... of creatinine than white patients, says a U.S. study ... is a standard indicator of kidney function. A higher ...
... 18 Sales leaders and,organizations that regularly ... art of motivating their sales representatives. Organizations ... personnel can use the key findings,discovered in ... &,Recognizing Top-Performing Sales People.",( http://www3.best-in-class.com/dr295.htm ), ...
... ARBOR, Mich. Right now, about half of all people ... help from it. And doctors have no definitive way to ... prescription they write. , But a University of Michigan ... more certainty to how doctors and patients choose anxiety treatments, ...
... as much as drug treatments , , FRIDAY, April 18 ... symptoms in patients with terminal cancer, according to Japanese ... included a total of 517 patients with incurable cancer ... treatment for these patients was supportive expressive group therapy, ...
Cached Medicine News:Health News:PCMA: Court of Appeals Upholds Challenge to D.C.'s PBM Fiduciary-Disclosure Law 2Health News:Muscle Mass May Not Explain High Creatinine in Black Kidney Patients 2Health News:Complementary Excerpt Available from Best Practices: Rewarding and Recognizing Top-Performing Sales People 2Health News:High anxiety? 2Health News:High anxiety? 3Health News:High anxiety? 4Health News:Talk Therapy Proves Effective for Terminal Cancer Patients 2
IGF-BP3 EIA Endocrine Function 022-IGF-E03 Insulin Growth Factor binding protein...
... Angiotensin Converting Enzyme (ACE) is an integral ... the generation of Angiotensin II as well ... many different cell types, ACE is primarily ... only an important diagnostic parameter for sarcoidosis ...
Anti-Gliadin IgG (Ab) EIA Gastrointestinal Markers 027-GD16 Celiac Disease Food Allergy...
... evaluation of pancreatic -cell function is not only ... of the natural history of diabetes mellitus, but ... guide to the correct choice of treatment. Peripheral ... function because of the large and variable uptake ...
Medicine Products: